Symbiotec Pharmalab Ltd Q2 FY27 Results Analysis: Revenue Jumps 43%, EBITDA Margin Rebounds
Symbiotec Pharmalab Ltd's Q2 FY27 numbers came in strong, with revenue of Rs. 279.93 Cr (+43.20% YoY) and PAT growth of +169.10% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | November 05, 2026 |
|---|---|
| Revenue (Q2) | Rs. 279.93 Cr (+43.20% YoY) |
| PAT (Q2) | Rs. 51.72 Cr (+169.10% YoY) |
| EBITDA margin | 32.70% (+700 bps YoY) |
| EPS (Q2) | Rs. 8.20 (+137.70% YoY) |
Quarter Snapshot
Q2 FY27 revenue grew 43.2% YoY with EBITDA margin rebounding to 32.7% from 20.7% in Q1 on gross-margin expansion, and H1 is tracking ahead of management's FY27 guidance of +20% revenue and +25% EBITDA. The IPO-funded deleveraging cut net debt to Rs.311.38 Cr, but cash conversion is the weak spot with H1 CFO at 0.70x PAT and negative free cash flow of −Rs.67.60 Cr on working-capital builds. H2 requires Rs.544.90 Cr revenue and Rs.160.51 Cr EBITDA with guided milestone cash flows still to land.
Q2 FY27 Expectations vs Results
| Driver | What happened | Verdict |
|---|---|---|
| Revenue "in-line-to-ahead vs Q1's +7.4% YoY" on bulk-drug export flow | +43.2% YoY / +28.3% QoQ — ahead | Played out |
| Gross margin "flat-to-compressing vs Q1's 65%" on feedstock/solvent/freight | 71.6% — expanded ~620 bps QoQ — this quarter | Contradicted |
| API EBITDA margin (~31% Q1) "the line to test" | Single-segment filing; no API split | Not observable |
| FY27 +20%/+25% path "still plausible" | H1 +24.9% revenue, +26.3% EBITDA | Played out |
| No Q2 milestone recognition evidenced | Other income Rs.0.11 Cr; no milestone disclosed — consistent | Played out |
| New-business drag continues (~Rs.23 Cr opex/~Rs.11 Cr D&A) | D&A flat QoQ; opex not split in filing | Not observable |
| Solvent/freight/soyabean headwinds to show in margins | Not visible in the cost lines — this quarter | Contradicted |
Management Guidance vs Delivery
| What management said | What happened | Verdict |
|---|---|---|
| FY27 revenue +20% (±5%) | H1 +24.9% YoY; Q2 +43.2% | On Track |
| FY27 EBITDA +25% (±5%) | H1 +26.3% YoY (ex-exceptional basis) | On Track |
| PAT growth slightly lower than EBITDA | H1 PAT +33.9% vs EBITDA +26.3% — currently ahead, aided by deferred-tax credits | On Track |
| Cash PAT growth "upwards of 25%" | H1 +55.9% YoY | On Track |
| Capex Rs.200–250 Cr annually | H1 Rs.113.54 Cr (Q2 derived ~Rs.45.5 Cr) | On Track |
| DCV/CDMO milestone cash flows H2 FY27 | No milestone line in Q2 | Too Early |
| API growth "expected to pick up in subsequent quarters" | Q2 consolidated revenue +43.2% YoY / +28.3% QoQ vs Q1's +7.4% — directionally | Confirmed |
| First couple of quarters "lumpy" on new-business drag; strong H2 on milestones | Q2 EBITDA margin rebounded to 32.7% from 20.7%; H2 milestones not yet due | Confirmed for Q2; H2 Too Early |
| DCV agreement "just a whisker away" | Signed September 30, 2026 (per announcements; not a P&L item in Q2) | Confirmed |
| Europe 10-yr take-or-pay signing "very soon" | Not addressed in the filing | Too Early |
Key Investment Insights
Key Positives
- Revenue grew 43.2% YoY to Rs.279.93 Cr, accelerating from Q1's +7.4% YoY; H1 revenue Rs.498.08 Cr, +24.9% YoY
- EBITDA of Rs.91.51 Cr grew 82.0% YoY and 102.5% QoQ, with margin at 32.7% vs 20.7% in Q1
- Gross margin expanded to 71.6% from 65.4% in Q1 and 64.1% in Q2 FY26; raw material cost fell to 28.4% of revenue
- Net profit grew 169.1% YoY to Rs.51.72 Cr; ex-deferred-tax-credit PAT of Rs.47.10 Cr still grew 141.9% YoY
- Net debt fell Rs.66.41 Cr since March to Rs.311.38 Cr after IPO proceeds prepaid Rs.112.50 Cr of borrowings; finance costs fell 10.7% YoY
- H1 tracking ahead of FY27 guidance: revenue +24.9% vs +20% target, EBITDA +26.3% vs +25% target, cash PAT +55.9% vs 'upwards of 25%' target
- Subsidiaries contributed positively: Rs.3.19 Cr of PAT (6.2% of consolidated) and Rs.31.53 Cr of EBITDA
Risk Factors
- H1 operating cash flow of Rs.45.94 Cr was only 0.70x PAT (0.34x EBITDA) and free cash flow was negative at −Rs.67.60 Cr
- Working capital deteriorated: DSO rose to 98 days (from 83 at March) and inventory days to 110.8 (from 99.5)
- Other expenses rose 65.2% YoY and 21.3% QoQ, though the new-business component (~Rs.23 Cr/qtr guided) is not split out
- D&A more than doubled YoY (+106.6%) to Rs.21.87 Cr/quarter on new-business assets
- Effective tax rate of 19.3% (vs 42.6% YoY) was flattered by a Rs.4.62 Cr deferred-tax credit; cash tax rate is 26.5%
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.